Interactive Case Study – Catalytic Health

Post-Case Assessment Questions

1 / 5

1. What are the currently-funded treatment options in Canada for patients with MM relapsing after first-line treatment with DRd? (select all that apply)

A. Kd

B. KRd

C. XVd

D. IsaPd

2 / 5

2. Which factors impact your recommendation for this patient’s second-line treatment? (select one)

A. Age ≥65 years

B. Hypertension comorbidity

C. High risk cytogenetics

D. Renal impairment

E. Distance to treatment centre

F. All of the above

3 / 5

3. Which patient and/or disease characteristics have been associated with improved PFS in response to treatment with XVd in the BOSTON study? (select all that apply)

A. Prior lenalidomide

B. Prior bortezomib

C. Age less than 65 years

D. High-risk cytogenetics

4 / 5

4. What considerations would you make to determine the starting dose of selinexor? (select all that apply)

A. Age

B. Fitness

C. High-risk disease

D. Prior resistance to lenalidomide

E. Prior treatment related AEs

5 / 5

5. How can the potential gastrointestinal AEs related to selinexor best be mitigated?

A. Anti-emetics (i.e.Akynzeo) use after symptoms start

B. Dual anti-emetics (ie. Akynzeo) use from the start of treatment

C. Dexamethasone in XVd is sufficient

Your score is

By WordPress Quiz plugin